公开(公告)号：US10646549B2

公开(公告)日：2020-05-12

申请号：US16192274

申请日：2018-11-15

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Susannah Hewitt ,  Ailin Bai ,  Stephen Hoge ,  Vladimir Presnyak ,  Iain Mcfadyen ,  Kerry Benenato ,  Ellalahewage Sathyajith Kumarasinghe

IPC: A61K48/00 ,  A61K38/20 ,  A61K9/51 ,  C07K14/54 ,  A61P35/00 ,  A61K9/00

Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.

公开(公告)号：US12103955B2

公开(公告)日：2024-10-01

申请号：US16944014

申请日：2020-07-30

Applicant: MODERNATX, INC.

Inventor： Barry Ticho ,  Nadege Briancon-Eris ,  Zhinan Xia ,  Athanasios Dousis ,  Seymour de Picciotto ,  Vladimir Presnyak ,  Stephen Hoge ,  Iain Mcfadyen ,  Kerry Benenato ,  Ellalahewage Sathyajith Kumarasinghe

IPC: C12N15/62 ,  A61K31/7105 ,  A61K38/17 ,  A61K47/14 ,  A61K47/69 ,  A61K48/00 ,  A61P9/00 ,  C07K14/64 ,  C07K16/26 ,  C12N15/52 ,  A61K9/00 ,  A61K9/127 ,  A61K38/00

CPC classification number: C07K14/64 ,  A61K31/7105 ,  A61K38/1796 ,  A61K47/6929 ,  A61P9/00 ,  C07K16/26 ,  C12N15/52 ,  C12N15/62 ,  A61K9/0019 ,  A61K9/127 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/31

Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.

公开(公告)号：US20190275170A1

公开(公告)日：2019-09-12

申请号：US16302607

申请日：2017-05-18

Applicant: ModernaTX, Inc.

Inventor： Kerry Benenato ,  Stephen Hoge ,  Paolo Martini ,  Iain Mcfadyen ,  Vladimir Presnyak ,  Ding An ,  Ellalahewage Sathyajith Kumarasinghe

IPC: A61K48/00 ,  A61K9/51 ,  A61K47/14 ,  A61K47/16 ,  A61K47/22 ,  A61K47/24 ,  C12N15/88

Abstract: The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG 1), isoforms thereof functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

公开(公告)号：US10322090B2

公开(公告)日：2019-06-18

申请号：US16184282

申请日：2018-11-08

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen Hoge ,  Kerry Benenato ,  Iain Mcfadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K48/00 ,  A61K9/51 ,  A61K38/17 ,  A61K38/20 ,  A61K9/00 ,  A61K39/39 ,  A61K45/06 ,  A61K9/127 ,  C07K14/54 ,  C07K14/545 ,  C07K14/705 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  B82Y5/00 ,  C12N15/88

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

公开(公告)号：US20190060246A1

公开(公告)日：2019-02-28

申请号：US16184282

申请日：2018-11-08

Applicant: ModernaTX, Inc.

Inventor： Joshua Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen Hoge ,  Kerry Benenato ,  Iain Mcfadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K9/51 ,  C07K14/705 ,  A61P35/00 ,  C07K14/54 ,  C07K14/545 ,  A61K9/00 ,  A61K9/127 ,  A61K38/17 ,  A61K48/00 ,  A61K45/06 ,  A61K39/395 ,  A61K39/39 ,  A61K38/20 ,  A61K39/00

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

公开(公告)号：US12128113B2

公开(公告)日：2024-10-29

申请号：US16302607

申请日：2017-05-18

Applicant: ModernaTX, Inc.

Inventor： Kerry Benenato ,  Stephen Hoge ,  Paolo Martini ,  Iain Mcfadyen ,  Vladimir Presnyak ,  Ding An ,  Ellalahewage Sathyajith Kumarasinghe

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/51 ,  A61K47/00 ,  A61K47/14 ,  A61K47/16 ,  A61K47/22 ,  A61K47/24 ,  C12N15/88 ,  A61K9/127 ,  A61K47/10 ,  A61K47/28 ,  C07K14/705

CPC classification number: A61K48/0066 ,  A61K9/51 ,  A61K47/14 ,  A61K47/16 ,  A61K47/22 ,  A61K47/24 ,  A61K48/0041 ,  C12N15/88 ,  A61K9/1271 ,  A61K9/5123 ,  A61K47/10 ,  A61K47/28 ,  C07K14/705

Abstract: The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

公开(公告)号：US11851694B1

公开(公告)日：2023-12-26

申请号：US16794318

申请日：2020-02-19

Applicant: ModernaTX, Inc.

Inventor： David Mauger ,  Vladimir Presnyak ,  Amy E. Rabideau ,  Iain Mcfadyen

IPC: C12P19/34 ,  C12N15/11

CPC classification number: C12P19/34 ,  C12N15/11

Abstract: The present disclosure provides methods and compositions for high fidelity in vitro transcription reactions.

公开(公告)号：US20230250439A1

公开(公告)日：2023-08-10

申请号：US18093119

申请日：2023-01-04

Applicant: ModernaTX, Inc.

Inventor： David Mauger ,  Iain Mcfadyen ,  Vladimir Presnyak

IPC: C12N15/67 ,  A61K48/00

CPC classification number: C12N15/67 ,  A61K48/0066

Abstract: The disclosure relates to synthetic thermostable polynucleotides, as well as methods of synthesizing and delivering the polynucleotides.

公开(公告)号：US11649461B2

公开(公告)日：2023-05-16

申请号：US16570351

申请日：2019-09-13

Applicant: ModernaTX, Inc.

Inventor： Paolo Martini ,  Stephen G. Hoge ,  Kerry Benenato ,  Vladimir Presnyak ,  Iain Mcfadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Xuling Zhu ,  Lin Tung Guey ,  Staci Sabnis

IPC: A61K48/00 ,  C12N15/67 ,  A61K9/51 ,  C12N9/40 ,  A61P3/00 ,  A61K38/47

CPC classification number: C12N15/67 ,  A61K9/5123 ,  A61K38/47 ,  A61P3/00 ,  C12N9/2465 ,  C12Y302/01022 ,  A61K48/00

Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.

公开(公告)号：US20210268086A1

公开(公告)日：2021-09-02

申请号：US17255949

申请日：2019-06-27

Applicant: ModernaTX, Inc.

Inventor： Shan Zhong ,  Benjamin Breton ,  Iain Mcfadyen ,  Kristen Hopson ,  Vincent Luczkow ,  Maija Garnaas

IPC: A61K39/00 ,  G16B20/20 ,  G16B20/30 ,  G16B30/00 ,  G01N33/50 ,  G16B40/00 ,  A61P35/00 ,  A61P37/04

Abstract: The disclosure relates to optimized cancer vaccines, as well as methods of making the vaccines, using the vaccines, and compositions comprising the vaccines. The cancer vaccines comprise personalized cancer antigens or portions of cancer hotspot antigens. Additionally, the disclosure relates to a computerized system for selecting nucleic acids to include in an optimized cancer vaccine.